Selective, tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses

Ko Chung Lin, Humayun S. Ateeq, Sherry H. Hsiung, Lillian T. Chong, Craig N. Zimmerman, Alfredo Castro, Wen Cherng Lee, Charles E. Hammond, Sandhya Kalkunte, Ling Ling Chen, R. Blake Pepinsky, Diane R. Leone, Andrew G. Sprague, William M. Abraham, Alan Gill, Roy R. Lobb, Steven P. Adams

Research output: Contribution to journalArticle

188 Citations (Scopus)

Abstract

Integrin α4β1 mediates leukocyte recruitment, activation, mediator release, and apoptosis inhibition, and it plays a central role in inflammatory pathophysiology. High-affinity, selective inhibitors of α4β1, based on the Leu-Asp-Val (LDV) sequence from the alternatively spliced connecting segment-1 (CS-1) peptide of cellular fibronectin, are described that employ a novel N-terminal peptide 'cap' strategy. One inhibitor, BIO- 1211, was ~106-fold more potent than the starting peptide and exhibited tight-binding properties (k(off) = 1.4 x 10-4 s-1, K(D) = 70 pM), a remarkable finding for a noncovalent, small-molecule inhibitor of a protein receptor. BIO-1211 was also 200-fold selective for the activated form of α4β1, and it stimulated expression of ligand-induced epitopes on the integrin β1 subunit, a property consistent with occupancy of the receptor's ligand-binding site. Pretreatment of allergic sheep with a 3-mg nebulized dose of BIO-1211 inhibited early and late airway responses following antigen challenge and prevented development of nonspecific airway hyperresponsiveness to carbachol. These results show that highly selective and potent small- molecule antagonists can be identified to integrins with primary specificity for peptide domains other than Arg-Gly-Asp (RGD); they confirm the generality of integrins as small molecule targets; and they validate α4β1 as a therapeutic target for asthma.

Original languageEnglish
Pages (from-to)920-934
Number of pages15
JournalJournal of Medicinal Chemistry
Volume42
Issue number5
DOIs
StatePublished - Mar 11 1999
Externally publishedYes

Fingerprint

Integrins
Peptides
leucyl-aspartyl-valine
Molecules
Ligands
Carbachol
Fibronectins
Epitopes
Sheep
Leukocytes
Asthma
Chemical activation
Binding Sites
Apoptosis
Antigens
BIO 1211
Proteins
Therapeutics

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Lin, K. C., Ateeq, H. S., Hsiung, S. H., Chong, L. T., Zimmerman, C. N., Castro, A., ... Adams, S. P. (1999). Selective, tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses. Journal of Medicinal Chemistry, 42(5), 920-934. https://doi.org/10.1021/jm980673g

Selective, tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses. / Lin, Ko Chung; Ateeq, Humayun S.; Hsiung, Sherry H.; Chong, Lillian T.; Zimmerman, Craig N.; Castro, Alfredo; Lee, Wen Cherng; Hammond, Charles E.; Kalkunte, Sandhya; Chen, Ling Ling; Pepinsky, R. Blake; Leone, Diane R.; Sprague, Andrew G.; Abraham, William M.; Gill, Alan; Lobb, Roy R.; Adams, Steven P.

In: Journal of Medicinal Chemistry, Vol. 42, No. 5, 11.03.1999, p. 920-934.

Research output: Contribution to journalArticle

Lin, KC, Ateeq, HS, Hsiung, SH, Chong, LT, Zimmerman, CN, Castro, A, Lee, WC, Hammond, CE, Kalkunte, S, Chen, LL, Pepinsky, RB, Leone, DR, Sprague, AG, Abraham, WM, Gill, A, Lobb, RR & Adams, SP 1999, 'Selective, tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses', Journal of Medicinal Chemistry, vol. 42, no. 5, pp. 920-934. https://doi.org/10.1021/jm980673g
Lin, Ko Chung ; Ateeq, Humayun S. ; Hsiung, Sherry H. ; Chong, Lillian T. ; Zimmerman, Craig N. ; Castro, Alfredo ; Lee, Wen Cherng ; Hammond, Charles E. ; Kalkunte, Sandhya ; Chen, Ling Ling ; Pepinsky, R. Blake ; Leone, Diane R. ; Sprague, Andrew G. ; Abraham, William M. ; Gill, Alan ; Lobb, Roy R. ; Adams, Steven P. / Selective, tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses. In: Journal of Medicinal Chemistry. 1999 ; Vol. 42, No. 5. pp. 920-934.
@article{033b9962375e4805b6cbe440863b0702,
title = "Selective, tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses",
abstract = "Integrin α4β1 mediates leukocyte recruitment, activation, mediator release, and apoptosis inhibition, and it plays a central role in inflammatory pathophysiology. High-affinity, selective inhibitors of α4β1, based on the Leu-Asp-Val (LDV) sequence from the alternatively spliced connecting segment-1 (CS-1) peptide of cellular fibronectin, are described that employ a novel N-terminal peptide 'cap' strategy. One inhibitor, BIO- 1211, was ~106-fold more potent than the starting peptide and exhibited tight-binding properties (k(off) = 1.4 x 10-4 s-1, K(D) = 70 pM), a remarkable finding for a noncovalent, small-molecule inhibitor of a protein receptor. BIO-1211 was also 200-fold selective for the activated form of α4β1, and it stimulated expression of ligand-induced epitopes on the integrin β1 subunit, a property consistent with occupancy of the receptor's ligand-binding site. Pretreatment of allergic sheep with a 3-mg nebulized dose of BIO-1211 inhibited early and late airway responses following antigen challenge and prevented development of nonspecific airway hyperresponsiveness to carbachol. These results show that highly selective and potent small- molecule antagonists can be identified to integrins with primary specificity for peptide domains other than Arg-Gly-Asp (RGD); they confirm the generality of integrins as small molecule targets; and they validate α4β1 as a therapeutic target for asthma.",
author = "Lin, {Ko Chung} and Ateeq, {Humayun S.} and Hsiung, {Sherry H.} and Chong, {Lillian T.} and Zimmerman, {Craig N.} and Alfredo Castro and Lee, {Wen Cherng} and Hammond, {Charles E.} and Sandhya Kalkunte and Chen, {Ling Ling} and Pepinsky, {R. Blake} and Leone, {Diane R.} and Sprague, {Andrew G.} and Abraham, {William M.} and Alan Gill and Lobb, {Roy R.} and Adams, {Steven P.}",
year = "1999",
month = "3",
day = "11",
doi = "10.1021/jm980673g",
language = "English",
volume = "42",
pages = "920--934",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Selective, tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses

AU - Lin, Ko Chung

AU - Ateeq, Humayun S.

AU - Hsiung, Sherry H.

AU - Chong, Lillian T.

AU - Zimmerman, Craig N.

AU - Castro, Alfredo

AU - Lee, Wen Cherng

AU - Hammond, Charles E.

AU - Kalkunte, Sandhya

AU - Chen, Ling Ling

AU - Pepinsky, R. Blake

AU - Leone, Diane R.

AU - Sprague, Andrew G.

AU - Abraham, William M.

AU - Gill, Alan

AU - Lobb, Roy R.

AU - Adams, Steven P.

PY - 1999/3/11

Y1 - 1999/3/11

N2 - Integrin α4β1 mediates leukocyte recruitment, activation, mediator release, and apoptosis inhibition, and it plays a central role in inflammatory pathophysiology. High-affinity, selective inhibitors of α4β1, based on the Leu-Asp-Val (LDV) sequence from the alternatively spliced connecting segment-1 (CS-1) peptide of cellular fibronectin, are described that employ a novel N-terminal peptide 'cap' strategy. One inhibitor, BIO- 1211, was ~106-fold more potent than the starting peptide and exhibited tight-binding properties (k(off) = 1.4 x 10-4 s-1, K(D) = 70 pM), a remarkable finding for a noncovalent, small-molecule inhibitor of a protein receptor. BIO-1211 was also 200-fold selective for the activated form of α4β1, and it stimulated expression of ligand-induced epitopes on the integrin β1 subunit, a property consistent with occupancy of the receptor's ligand-binding site. Pretreatment of allergic sheep with a 3-mg nebulized dose of BIO-1211 inhibited early and late airway responses following antigen challenge and prevented development of nonspecific airway hyperresponsiveness to carbachol. These results show that highly selective and potent small- molecule antagonists can be identified to integrins with primary specificity for peptide domains other than Arg-Gly-Asp (RGD); they confirm the generality of integrins as small molecule targets; and they validate α4β1 as a therapeutic target for asthma.

AB - Integrin α4β1 mediates leukocyte recruitment, activation, mediator release, and apoptosis inhibition, and it plays a central role in inflammatory pathophysiology. High-affinity, selective inhibitors of α4β1, based on the Leu-Asp-Val (LDV) sequence from the alternatively spliced connecting segment-1 (CS-1) peptide of cellular fibronectin, are described that employ a novel N-terminal peptide 'cap' strategy. One inhibitor, BIO- 1211, was ~106-fold more potent than the starting peptide and exhibited tight-binding properties (k(off) = 1.4 x 10-4 s-1, K(D) = 70 pM), a remarkable finding for a noncovalent, small-molecule inhibitor of a protein receptor. BIO-1211 was also 200-fold selective for the activated form of α4β1, and it stimulated expression of ligand-induced epitopes on the integrin β1 subunit, a property consistent with occupancy of the receptor's ligand-binding site. Pretreatment of allergic sheep with a 3-mg nebulized dose of BIO-1211 inhibited early and late airway responses following antigen challenge and prevented development of nonspecific airway hyperresponsiveness to carbachol. These results show that highly selective and potent small- molecule antagonists can be identified to integrins with primary specificity for peptide domains other than Arg-Gly-Asp (RGD); they confirm the generality of integrins as small molecule targets; and they validate α4β1 as a therapeutic target for asthma.

UR - http://www.scopus.com/inward/record.url?scp=0033545639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033545639&partnerID=8YFLogxK

U2 - 10.1021/jm980673g

DO - 10.1021/jm980673g

M3 - Article

C2 - 10072689

AN - SCOPUS:0033545639

VL - 42

SP - 920

EP - 934

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 5

ER -